Bcl2 Deficiency Activates FoxO through Akt Inactivation and Accelerates Osteoblast Differentiation-Reference-Cited by-同舟云学术

Bcl2 Deficiency Activates FoxO through Akt Inactivation and Accelerates Osteoblast Differentiation

Published:2014-01-20 Issue:1 Volume:9 Page:e86629
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Moriishi Takeshi,Kawai Yosuke,Komori Hisato,Rokutanda Satoshi,Eguchi Yutaka,Tsujimoto Yoshihide,Asahina Izumi,Komori Toshihisa

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards;RL Jilka;J Bone Miner Res,2007

2. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength;CA O'Brien;Endocrinology,2004

3. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity;S Kousteni;Cell,2001

4. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1–34) fragment;D Stanislaus;Bone,2000

5. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro;A Gohel;Endocrinology,1999

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The miR‐184‐3p promotes rice black‐streaked dwarf virus infection by suppressing Ken in Laodelphax striatellus (Fallén);Pest Management Science;2023-12-21

2. Bcl2l1 Deficiency in Osteoblasts Reduces the Trabecular Bone Due to Enhanced Osteoclastogenesis Likely through Osteoblast Apoptosis;International Journal of Molecular Sciences;2023-12-10

3. Molecular mechanism of a novel root-end filling material containing zirconium oxide on the osteogenic/odontogenic differentiation of human osteosarcoma MG-63 cells;Frontiers in Bioengineering and Biotechnology;2023-10-13

4. PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia;Blood Cancer Journal;2023-09-07

5. Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth;Scientific Reports;2023-05-17